Lanean...
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
Platinum chemotherapy remains the cornerstone of treatment for epithelial ovarian cancer (OC) and Poly (ADP-ribose) polymerase inhibitors (PARPi) now have an established role as maintenance therapy. The mechanisms of action of these agents is, in many ways, complementary, and crucially reliant on th...
Gorde:
Egile Nagusiak: | , , , |
---|---|
Formatua: | Artigo |
Hizkuntza: | Inglês |
Argitaratua: |
MDPI AG
2020-06-01
|
Saila: | Cancers |
Gaiak: | |
Sarrera elektronikoa: | https://www.mdpi.com/2072-6694/12/6/1607 |
Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|